Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment

RELATED NEWS
Trade CTIC now with 

Cell Therapeutics, Inc. (CTIC: Quote) on Tuesday said the University of Washington's School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme.

The study objective is to determine whether paclitaxel poliglumex and RT are likely to improve progression-free survival and overall survival compared to TMZ and RT. It will also evaluate neuro-cognitive function and toxicities of these therapies.

Glioblastoma multiforme or GBM is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT, which substantially decreases the effectiveness of standard therapy with TMZ.

This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group in Providence, Rhode Island. The first patient at UW recently has been enrolled.

Click here to receive FREE breaking news email alerts for CTI BioPharma Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast. Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.